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Abstract
Adenoid cystic carcinoma (ACC) is a rare cancer that preferentially occurs in the head and neck, breast, as well as in
other sites. It is an aggressive cancer with high rates of recurrence and distant metastasis. Patients with advanced
disease are generally incurable due to the lack of effective systemic therapies. Activation of the master transcriptional
regulator MYB is the genomic hallmark of ACC. MYB activation occurs through chromosomal translocation, copy
number gain or enhancer hijacking, and is the key driving event in the pathogenesis of ACC. However, the functional
consequences of alternative mechanisms of MYB activation are still uncertain. Here, we show that overexpression of
MYB or MYB-NFIB fusions leads to transformation of human glandular epithelial cells in vitro and results in analogous
cellular and molecular consequences. MYB and MYB-NFIB expression led to increased cell proliferation and
upregulation of genes involved in cell cycle control, DNA replication, and DNA repair. Notably, we identified the DNA-
damage sensor kinase ATR, as a MYB downstream therapeutic target that is overexpressed in primary ACCs and ACC
patient-derived xenografts (PDXs). Treatment with the clinical ATR kinase inhibitor VX-970 induced apoptosis in MYB-
positive ACC cells and growth inhibition in ACC PDXs. To our knowledge, ATR is the first example of an actionable
target downstream of MYB that could be further exploited for therapeutic opportunities in ACC patients. Our findings
may also have implications for other types of neoplasms with activation of the MYB oncogene.
Introduction
Adenoid cystic carcinoma (ACC) is a clinically chal-
lenging tumor that preferentially occurs in the salivary
glands but may also arise in other exocrine glands such as
those of the breast, prostate, skin, sinonasal tract, tra-
cheobronchial tree, and female genital tract1. ACC can
occur in all age groups but is commonly diagnosed
between 50 and 60 years of age2. It is usually a slow
growing but aggressive cancer with an often protracted
clinical course and a fatal outcome. ACCs are treated with
surgery and adjuvant radiotherapy. However, the majority
of patients develop recurrences and/or distant metastases
over time and, since there are no effective systemic
therapies available for ACC, patients with advanced dis-
ease are generally incurable3,4. The genomic hallmark of
ACC is a recurrent t(6;9)(q23;p23) translocation5 that
results in a fusion between the MYB and NFIB genes6.
MYB is an oncogenic transcription factor that regulates
proliferation and differentiation of in particular hemato-
poetic and colonic stem and progenitor cells7. NFIB is a
transcriptional regulator that controls cell division, dif-
ferentiation, and viability8. In the MYB-NFIB fusions, the
DNA-binding and transactivation domains of MYB are
fused to the C-terminal of NFIB, often encoded only by
the last exon, leading to overexpression of MYB and loss
of negative regulatory elements in the C-terminal part of
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MYB6. In addition to gene fusion, MYB may be activated
by copy number gain or juxtaposition of enhancer ele-
ments from NFIB, RAD51B or TGFBR39,10. These rear-
rangements result in overexpression of a normal wild-type
MYB protein, whereas the fusion events commonly result
in expression of truncated MYB proteins. In a subset of
ACCs, MYB is replaced by the closely related MYBL1
gene linked to NFIB, or other fusion partners, resulting in
gene fusions likely to have the same oncogenic properties
as the MYB fusions11,12. MYB activation occurs in the vast
majority of ACCs and is therefore considered to be the
main oncogenic driver of the disease and a potential
therapeutic target1. MYB overexpression is also a useful
diagnostic biomarker to distinguish ACC from other types
of salivary gland tumors13. The concept that MYB is a key
driver of ACC is corroborated by whole-exome sequen-
cing and arrayCGH studies of salivary and breast ACCs
showing that ACC generally has a stable genome with few
other mutations and copy number alterations9,14,15.
Moreover, recent studies have demonstrated that knock-
down of MYB-NFIB expression in cultured, fusion-
positive ACC cells results in reduced cell proliferation
and decreased ACC spherogenesis under anchorage-
independent growth conditions16.
Although there is substantial evidence indicating a key
role for MYB in ACC pathogenesis, experimental evi-
dence demonstrating that MYB can transform normal
human glandular epithelial cells is lacking. Moreover,
since ACC cells are exceedingly difficult to grow in cul-
ture, preclinical therapeutic target discovery downstream
of MYB is severely hampered by the lack of established
cell lines16,17. Here, we investigate the transforming
potential and molecular consequences of MYB and MYB-
NFIB overexpression in human mammary epithelial cells
and cultured ACC cells. We identify the DNA-damage
sensor kinase ATR as a MYB downstream therapeutic
target that is overexpressed in ACC and show that
treatment with a phase 2 ATR kinase inhibitor induce
apoptosis in MYB-positive ACC cells and growth inhibi-
tion in ACC patient-derived xenografts (PDXs).
Results
MYB and MYB-NFIB overexpression promote proliferation
of human breast epithelial cells
To study the transforming potential of MYB and MYB-
NFIB in non-tumorigenic glandular epithelial cells, we
generated stable MCF10A cell lines overexpressing wild-
type MYB or two common variants of the MYB-NFIB
fusion (M14N8C and M14N9). Ectopic expression of the
different MYB isoforms was confirmed by immunoblot
analysis (Supplementary Fig. 1). MYB and MYB-NFIB
overexpressing cells showed similar levels of increased
proliferation compared with cells infected with empty
vectors (Fig. 1a). To study whether this effect was MYB-
dependent, we treated the cells with naphthol phosphate
(NAS), an inhibitor of the interaction of MYB and CREB,
with the kix-domain of the CBP co-activator18,19. NAS
treatment reduced proliferation of MYB and MYB-NFIB
overexpressing cells whereas it did not significantly affect
the control cells (Fig. 1b). This indicates that the increased
proliferation is driven by MYB or MYB-NFIB over-
expression and is not a consequence of clonal selection of
the transduced cells.
MYB and MYB-NFIB promote EGF-independent cell cycle
progression and three-dimensional growth of human
breast epithelial cells
To study whether MYB proteins promote cell cycle
progression, we cultured the transduced cells in the pre-
sence or absence of EGF for 48 h following staining with
propidium iodide. As expected, flow cytometric analysis
showed a major change in cell cycle profiles in the
absence of EGF, with a larger fraction of cells residing in
the G1 phase of the cell cycle. However, under the same
conditions, MYB and MYB-NFIB overexpressing cells
were more abundant in the S-phase with less cells residing
in G1 compared with the control cells (Fig. 1c). These
results show that MYB oncoproteins promote cell cycle
progression also in glandular epithelial cells. MYB and
MYB-NFIB overexpressing MCF10A cells also formed
significantly larger (MYB: P= 0.009; M14N8C: P=
0.0057; M14N9: P= 0.0193) organoids when grown in the
absence of EGF in three-dimensional cultures (Fig. 2a, b).
Next, we investigated whether MYB and MYB-NFIB
overexpressing MCF10A cells were tumorigenic by
injecting them into the flank of immunodeficient mice.
No tumors were detected after a latency period of
5 months, indicating that stable MYB or MYB-NFIB
overexpression is not sufficient for tumor formation of
MCF10A cells (data not shown).
MYB and MYB-NFIB activate overlapping gene sets
involved in cell cycle regulation, DNA replication, and DNA
repair
To identify target genes that promote increased pro-
liferation of MYB and MYB-NFIB overexpressing
MCF10A cells, we performed global gene expression
analysis. Interestingly, there were four times more up-
than downregulated genes in MYB or MYB-NFIB trans-
duced cells, indicating that MYB is mainly a transcrip-
tional activator. More than 50% of the upregulated genes
(1370 genes) were shared between MYB and MYB-NFIB
whereas only 18% (131 genes) of the downregulated genes
were shared between the two MYB variants (Fig. 3a). To
confirm that our models are representative of MYB-
induced gene expression in ACC, we investigated the
association between gene sets derived from MYB/MYB-
NFIB overexpressing MCF10A cells compared with a
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previously published gene expression data set16 of MYB-
positive ACC patient samples (Supplementary Fig. 2).
There was a significant overlap (P < 0.0001) between
genes upregulated by MYB/MYB-NFIB in MCF10A cells
and those upregulated in MYB-positive ACC patient
samples.
Next, gene ontology analysis showed that the main
biological processes regulated by MYB and MYB-NFIB in
MCF10A cells were those involved in cell cycle, cell
division, DNA repair, mitosis, and DNA replication (Fig.
3b). Some of the activated genes are known MYB targets
(for example BIRC3, CDC2, and CXCR4) but most of the
genes have previously not been associated with MYB
(Supplementary Table 1). To validate these results we
performed a multiplex analysis with a qPCR panel con-
sisting of 27 genes upregulated by MYB or MYB-NFIB.
The expression of all 27 genes was increased in MYB or
MYB-NFIB expressing cells compared with control cells,
thus confirming the global gene expression data (Sup-
plementary Fig. 3).
The ATR kinase is a downstream target of MYB and MYB-
NFIB
Gene Set Enrichment Analysis (GSEA) revealed that
ATR/BRCA was the top activated pathway in MYB and
MYB-NFIB overexpressing cells (Fig. 3c, d). Particularly,
the ATR gene was significantly upregulated in these cells
(Fig. 3d, Supplementary Table 1) as well as in 14 MYB-
positive, ACC patient specimens (qPCR) and in eight
ACC PDX models (RNA-seq) compared with normal
salivary gland tissues (Fig. 3e, Supplementary Fig. 4).
Analyses of publicly available gene expression data sets
confirmed co-expression of MYB and ATR also in AML,
adult T-ALL, and colon carcinomas and adenomas
Fig. 1 Overexpression of MYB or MYB-NFIB fusions promote growth of cultured human breast epithelial cells. a Analysis of proliferation of
MCF10A cells transduced with retroviral expression vectors with MYB or two MYB-NFIB fusion variants (M14N8C and M14N9) using the MTT assay.
Cells transduced with empty vectors served as control. Error bars indicate standard error of the mean for triplicate wells (n= 3). b MCF10A cells
transduced with MYB or MYB-NFIB constructs were cultured for 48 h in the presence or absence of the MYB inhibitor Naphthol AS phosphate. Error
bars indicate standard error of the mean for triplicate wells (n= 3). c Cell cycle profiles of transduced MCF10A cells in the presence or absence of EGF
for 48 h. NAS – Naphthol AS phosphate, PI – propidium iodide. Asterisks indicate statistical significance with *P < 0.05; **P < 0.01; ***P < 0.001.
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(Supplementary Fig. 5). To investigate whether ATR is a
downstream target of MYB-NFIB in ACC, we analyzed
global gene expression data sets with siRNA knockdown
of MYB-NFIB in cultured ACC cells16. Treatment with
MYB siRNA caused a significant decrease in the expres-
sion of ATR, suggesting that MYB-NFIB regulates ATR
expression in ACC cells (Fig. 3f). Moreover, treatment of
ACC cells with the IGF1R inhibitors linsitinib or BMS-
754807, both known to downregulate MYB-NFIB
expression16, also caused a significant decrease in the
expression of ATR (Fig. 3g). Online chromatin immuno-
precipitation data sets further indicated that MYB binds
the ATR promoter in human and mouse cells (Supple-
mentary Fig. 6). Taken together, these findings strongly
indicate that ATR is a downstream target of MYB.
To assess the biological significance of ATR in cells with
MYB or MYB-NFIB overexpression, we treated trans-
duced MCF10A cells with the ATR inhibitor VX-970. The
proliferation of these cells was significantly decreased by
VX-970 and they also showed an increased sensitivity to
ATR inhibition compared with control cells (Fig. 3h).
Treatment with the ATR inhibitor VX-970 induces
apoptosis in cultured ACC cells and inhibits growth of ACC
PDXs
Next, we investigated whether pharmacological inhibi-
tion of ATR could be a potential therapeutic strategy for
ACC. Treatment of cultured MYB-NFIB positive ACC
cells (ACC 1 and ACC 2) with VX-970 generated a dose-
dependent decrease in proliferation and a significant
increase in apoptosis (Fig. 4a, b), indicating that ATR is
essential for ACC cell viability. To study whether ACCs
are sensitive to ATR inhibition in vivo, we used an ACC
PDX-model (ACCX20M1) with nuclear and cytoplasmic
ATR expression (Fig. 4c). Treatment with VX-970 for
eight weeks resulted in a significant tumor growth inhi-
bition (Fig. 4d). Notably, one mouse even showed tumor
regression (Supplementary Fig. 7). Tumor tissues from
treated mice showed a decrease in phospho-ATR com-
pared with untreated controls, which validate the on-
target effect of VX-970 (Fig. 4e).
Discussion
Activation of the master transcriptional regulator MYB
through chromosomal translocation, copy number gain,
or enhancer hijacking is the genomic hallmark of ACC9,10.
Thus, MYB and its downstream oncogenic effectors are
putative therapeutic targets in this disease. Here, we for
the first time show that overexpression of MYB and MYB-
NFIB fusions have analogous cellular consequences for
cell proliferation and transcriptional regulation of down-
stream target genes. We also identify the DNA-damage
sensor kinase ATR as a MYB and MYB-NFIB downstream
effector and a potential therapeutic target in ACC.
ATR is a critical component of the cellular DNA-
damage response (DDR) and is activated by replication
stress (RS)9,20. Oncogene-induced RS promotes an active
DDR that leads to induction of apoptosis or senescence,
Fig. 2 MYB and MYB-NFIB promote growth of human breast epithelial cells as organoids in three-dimensional culture. a Organoids formed
by MYB or MYB-NFIB fusion (M14N8C and M14N9) overexpressing MCF10A cells detected by transmission microscopy after 9 days of culture in
matrigel without EGF. b The area and perimeter of organoids were quantified as described in Materials and Methods. Error bars indicate standard
error of the mean for triplicate wells (n= 2). Asterisks indicate statistical significance with *P < 0.05; **P < 0.01.
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which provide natural barriers against tumorigenesis20. In
tumors with dysfunctional DDR, oncogene-induced RS
instead results in genomic instability and tumor pro-
gression21. In the present study, we show that MYB and
MYB-NFIB activate a significant number of DNA repair
genes, in addition to genes involved in cell cycle control
and DNA replication. These results are in accordance
with data from previously published siRNA knockdown
studies of MYB-NFIB in ACC cells16. It is thus likely that
overexpression of MYB and MYB-NFIB leads to an
oncogene-induced RS that initiates a DDR. ACCs are
inherently resistant to genotoxic stress3,4 and our data
implies that MYB-induced upregulation of DNA repair
pathways may, at least partly, be responsible for this
property.
Here, we present experimental evidence that the ATR
pathway is activated by MYB/MYB-NFIB in ACC through
transcriptional regulation. ATR was significantly upregu-
lated in non-tumorigenic breast epithelial cells over-
expressing MYB or MYB-NFIB fusions as well as in MYB-
Fig. 3 Global gene expression analysis of MYB and MYB-NFIB overexpressing human breast epithelial cells identifies activation of the ATR
pathway. a Euler diagrams illustrating the overlap between up- and downregulated genes in MYB and MYB-NFIB overexpressing MCF10A cells
compared with cells transduced with empty vectors. b Gene ontology analysis of genes upregulated by both MYB and MYB-NFIB in (a). c Gene set
enrichment analysis of genes upregulated by both MYB and MYB-NFIB showing enrichment of the ATR/BRCA pathway. d Heatmap visualizing ATR
pathway genes in MYB and MYB-NFIB overexpressing MCF10A cells. e Quantitative real-time PCR analysis of ATR and MYB expression in 14 primary
ACC patient samples vs 7 normal salivary gland (NSG) tissue samples. f Microarray gene expression analysis of ATR in cultured primary ACC cells
transfected with MYB siRNAs for 48 h. g Microarray gene expression analysis of ATR in cultured primary ACC cells treated with two different IGF1R
inhibitors for 24 h. h Analysis of proliferation of MYB and MYB-NFIB overexpressing MCF10A cells treated with the ATR kinase inhibitor VX-970 for 24 h.
Error bars indicate standard error of the mean for triplicate wells (n= 3). Asterisks indicate statistical significance with *P < 0.05; **P < 0.01; ***P <
0.001; ****P < 0.0001. CT – cycle threshold.
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positive, ACC patient samples and PDXs. Moreover,
knockdown of MYB-NFIB in cultured ACC cells caused a
significant decrease in ATR expression and there is evi-
dence that MYB binds the ATR promoter in both human
and mouse cells. Notably, analysis of global gene expres-
sion data sets revealed co-regulation of MYB and ATR
also in other human malignancies such as for example
AML, adult T-ALL, and colon carcinoma, indicating that
the link between MYB and ATR is not restricted to ACC
(Supplementary Fig. 5). Since cells undergoing oncogene-
induced RS require an intact ATR pathway to survive20,
we hypothesized that MYB overexpressing cells would be
sensitive to ATR inhibition. Indeed, when we treated
MCF10A cells overexpressing MYB or MYB-NFIB with
the phase 2 ATR kinase inhibitor VX-970 these cells
showed a marked decrease in cell proliferation compared
with control cells. In addition, VX-970 induced a dose-
dependent decrease in proliferation of cultured MYB-
positive ACC cells and a significant induction of apoptosis
in these cells. Treatment with VX-970 also led to sig-
nificant tumor growth inhibition in ACC PDXs and even
to tumor regression in one mouse. Interestingly, the PDX
tumors showed both nuclear and cytoplasmic localization
of ATR (Fig. 4c). This might suggest that a major function
of ATR in ACC is to promote tumor cell survival, in
agreement with a recent study showing a direct anti-
apoptotic function of cytoplasmic ATR at the level of
mitochondria22.
Preclinical studies have shown that ATR is essential for
survival of tumor cells with defective cell cycle check-
points or DNA repair20. Thus, ATR has emerged as an
interesting therapeutic target and there are currently close
to 40 ongoing clinical trials with ATR inhibitors in
patients with various human malignancies21 (clinicaltrials.
gov). Unfortunately, there are no available biomarkers
that can identify patients who will benefit from ATR
inhibition. However, the present data indicate that co-
expression of MYB and ATR could be a biomarker for
sensitivity to ATR inhibition. As a proof of principle, we
demonstrate that ATR inhibition leads to apoptosis in
MYB-positive ACC cells in vitro and growth inhibition of
ACC PDX tumors in vivo. These promising results will
serve as the basis for continued preclinical and clinical
studies of ATR inhibitors in neoplasms with co-
expression of MYB and ATR.
Depending on the mechanism of activation of MYB in
ACC (e.g., gene fusion, copy number gain or enhancer
hijacking) different isoforms of MYB are generated. We
now show that the effects on cell proliferation and tran-
scriptional regulation of downstream target genes are very
Fig. 4 The ATR kinase inhibitor VX-970 inhibits ACC cell proliferation in vitro and ACC PDX tumor growth in vivo. a Dose-response curves for
proliferation of short-term cultured ACC cells from two cases treated with the ATR kinase inhibitor VX-970 for 72 h. b Analysis of apoptosis in short-
term cultured cells from two ACCs treated with VX-970 for 24 h. c Immunohistochemical analysis of ATR and phospho-ATR (p-ATR) expression in
tissue sections from ACCX20M1 PDX tumors. d Tumor growth of ACC PDXs treated with oral administration of VX-970 at 60 mg/kg four times a week
during 60 days (control n= 10; VX-970 n= 7). e Quantification of the p-ATR to ATR protein expression ratio in the VX-970 treated ACC PDXs.
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similar irrespective of whether wild-type MYB proteins or
MYB-fusion proteins are overexpressed. This is in line
with a previous study showing similar gene expression
signatures in wild-type MYB and MYB fusion-positive
ACCs23. Furthermore, data from our laboratory suggests
that there are no major clinical differences between ACCs
with different genomic rearrangements of MYB (Persson
et al., unpublished results). Taken together, these results
indicate that wild-type and truncated MYB-fusion pro-
teins have very similar oncogenic effects in glandular
epithelial cells.
We also studied the transforming potential of the dif-
ferent MYB isoforms. MYB proteins promoted cell cycle
progression and formed significantly larger organoids in
three-dimensional cultures compared with controls.
However, when injected into the flank of immunodefi-
cient mice no tumors were detected after a latency period
of 5 months, indicating that stable MYB or MYB-NFIB
overexpression is not sufficient for tumor formation of
MCF10A cells. Additional genetic alterations, such as for
example mutations in the NOTCH or FGF-IGF-PI3K
pathways or copy number losses involving 1p and/or 6q,
are likely to be required for tumor formation9,14,15.
Preclinical studies of ACC suffer from the lack of
established ACC cell lines and the pronounced difficulties
to culture ACC cells, thus limiting the number of tumors
available for experimental studies. Another limitation of
this study is that only one ACC PDX-model was tested
and that ATR inhibition did not result in tumor regres-
sion in more than one mouse. This is, however, in line
with previous clinical observations that ACC is a
treatment-resistant cancer4. Notwithstanding these lim-
itations, our study has identified a new molecular target
that could be exploited for further therapeutic opportu-
nities in ACC patients.
In summary, we have shown that the DNA-damage
sensor kinase ATR is a MYB and MYB-NFIB downstream
effector and a novel therapeutic target in ACC. To our
knowledge, this is the first time a MYB downstream gene
has been successfully targeted in ACC. We also demon-
strate that overexpression of MYB and MYB-NFIB fusions
have analogous cellular and molecular consequences in
glandular epithelial cells. Our studies thus identify a novel
link between MYB and ATR in ACC that may have
implications also for other types of neoplasms with acti-
vation of the MYB oncogene.
Materials and methods
Tumor and normal tissues
Fresh tumor tissue from 14 head and neck ACCs and 7
normal salivary gland (NSG) tissues were obtained from
patient surgical specimens and total RNA was isolated as
previously described6,9,16. The study was approved by the
regional ethics committee in Gothenburg, Sweden (D-no:
178-08). The ethical committee waived the requirement
for informed consent due to no or minimal risk for the
patients and the use of patient material stripped of direct
subject identifiers.
Cell culture
MCF10A, a non-tumorigenic epithelial cell line
responsive to epidermal growth factor (EGF), was pur-
chased from ATCC. Cells were grown in DMEM/F12
medium (Invitrogen), supplemented with 20 ng/ml of
human epidermal growth factor (hEGF), 0.5 μg/ml
hydrocortisone, 100 ng/ml cholera toxin, 10 μg/ml insulin
(Sigma-Aldrich), 5% horse serum (Gibco/Thermofisher),
and 100 U/mL penicillin-streptomycin (Gibco, Thermo-
Fisher Scientific), according to previously described cul-
ture conditions24. Phoenix-AMPHO and HEK293FT were
grown in DMEM medium, supplemented with 10% FBS
and 100 U/mL penicillin-streptomycin (Gibco, Thermo-
Fisher Scientific). Human, MYB-NFIB fusion-positive
ACC cells were cultured as previously described6,16. The
ACC and MCF10A cells tested negative for mycoplasma
prior to experiments.
Plasmid construction and retroviral infection
Full-length coding sequences of MYB and two MYB-
NFIB fusion variants linking MYB exon 14 to NFIB exons
8C (M14N8C) or 9 (M14N9) were cloned into the
pMSCV vector using the XhoI site. Correct insertion of
cDNAs was confirmed by Sanger sequencing. For retro-
viral infections, Phoenix-AMPHO cells were seeded in
10 cm dishes. The following day, cells were co-transfected
using Lipofectamine 2000 reagent (Thermo Fisher) with
3.75 μg pPAX2 (gag-pol expressor), 1.5 μg pMDG.2 (VSV-
G expressor), and 5 μg of empty pMSCV, MYB, or MYB-
NFIB (M14N8C and M14N9) vectors and incubated with
the transfection mix overnight at 32 °C. The day after, the
transfection mix was replaced by medium specific for
MCF10A cells. Fourty-eight hours after transfections, the
medium was harvested, centrifuged at 2000 rpm for
30min and filtered. The medium containing the virus
particles was supplemented with polybrene (8 μg/ml) and
used to infect MCF10A cells. Twenty-four hours after
infections, the medium was replaced with fresh medium
and 48 h later G418 (800 μg/ml) was added for clonal
selection.
MCF10A cells transduced with control, MYB or MYB-
NFIB (M14N8C and M14N9) retroviral vectors, were
injected (2 × 106 cells) into the flanks of female NOD
SCID mice (n= 4 per group). Mice were observed for
5 months before being sacrificed and analyzed.
Preparation of protein extracts and western blot analysis
Cells were harvested, centrifuged at 1000 rpm for 5 min,
washed with phosphate-buffered saline (PBS), and cell
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pellets were resuspended in RIPA buffer (50 mM Tris-
HCl Ph 7.5, 150 mM NaCl, 0.5% sodium deoxycholate, 1%
IGEPAL® CA-630, 0.1% sodium dodecyl sulfate, 1 mM
phenylmethanesulfonyl fluoride, cOmplete™ Protease
Inhibitor Cocktail (all reagents supplied by Sigma-
Aldrich). After 20 min incubation on ice, lysates were
centrifuged at 13,000 rpm for 20 min to remove cell
debris. Protein extracts were quantified using the Pierce™
BCA Protein Assay Kit (Thermo Fisher Scientific),
according to manufacturer instructions. Protein extracts
were loaded on 8% gels (SureCast™ Acrylamide Solution
(40%), Invitrogen) and transferred to PVDF membranes
(Fisher Scientific). Western blot analyses were performed
using the following primary antibodies: c-MYB (sc-74512,
Santa Cruz Biotechnology) and Actin (sc-1616, Santa
Cruz Biotechnology). HRP-conjugated secondary anti-
bodies used were anti-mouse IgG (NXA931, GE Health-
care, Fisher Scientific) and anti-rabbit IgG (NA934, GE
Healthcare, Fisher Scientific). Antibody detection was
performed with enhanced chemiluminescence (ECL)
(Thermo Fisher Scientific).
Proliferation and apoptosis assays
One thousand MCF10A cells were seeded per well in
96-well plates and metabolic activity was quantified using
the CellTiter 96® AQueous MTS Reagent kit (Promega),
following manufacturer instructions. Four thousand ACC
cells were seeded per well in black 96-well plates (BD) and
treated the next day with different concentrations of the
ATR kinase inhibitor VX-970 (also known as VE-822 or
M6620; Selleck Chemicals) or DMSO as control. Cells
were assayed 72 h later with the Alamar blue reagent
(Thermo Fisher Scientific) according to instructions of the
manufacturer. For apoptosis assays, 8000 ACC cells were
seeded in white-walled 96-well plates (BD) and treated the
next day with 1 or 10 μM VX-970 for 24 h. Apoptosis was
assayed with the Caspase-Glo 3/7 reagent (Promega).
Cell cycle analysis
Three million MCF10A cells were seeded in T75 flasks
and cultured for 48 h with or without EGF. Cells were
harvested, washed with PBS, fixed in 70% ethanol and
kept at −20 °C overnight. The following day, cells were
washed twice with PBS to remove ethanol, and resus-
pended in 1ml of PBS containing RNaseA (100 μg/ml)
and propidium Iodide (50 μg/ml) (Sigma-Aldrich). Cell
cycle analysis was performed using a NovoCyte Cyt-
ometer using the NovoExpress 1.2.1 software.
RNA isolation, cDNA synthesis, and quantitative real-time
PCR (qPCR)
Total cellular RNA was extracted from MCF10A cells
using the TRIzol Reagent (Thermo Fisher Scientific), and
from short-term cultured ACC cells using the RNeasy
Micro Kit (Qiagen), following the manufacturers’
instructions. TRIzol extracted RNA was incubated with
deoxyribonuclease I (DNase I, Amp Grade; Invitrogen) at
37 °C for 1 h and reverse transcribed using a high capacity
RNA-to-cDNA kit. RNeasy extracted RNA was reverse
transcribed with the iScript cDNA Synthesis Kit (Bio-
Rad). Expression of MYB and 27 MYB target genes were
analyzed using custom TaqMan array plates (Supple-
mentary Table 2) and with single TaqMan assays
(Thermo Fisher Scientific) for ATR (Hs00354787_m1)
and MYB (Hs00920556_m1*). UBC (Hs01871556_s1) was
used as a reference gene.
Three-dimensional cell cultures
Three-dimensional MCF10a cell cultures were estab-
lished as previously described25. In brief, cells were
embedded in growth factor reduced Matrigel (Corning™
Matrigel™) and seeded on Matrigel precoated slides
(Merck™ Millicell™ EZ Slides, Millipore). The embedded
cells were fed with medium without EGF every second day.
Organoids (cell acini) were fixed with 4% paraformaldehyde
for 10min and washed twice with PBS. Area and perimeter
of the organoids were estimated using the ImageJ software.
ACC PDX drug testing
The antitumor activity of the ATR kinase inhibitor VX-
970 (LC Laboratories) was studied in the ACC PDX-
model, ACCX20M126, at South Texas Accelerated
Research Therapeutics (START) under Institutional
Animal Care and Use Committee-approved guidelines.
Six to eight weeks old athymic nude mice (Charles River
Labs) were implanted with ACC tumor fragments. Once
tumors reached 150–250mm3, animals were randomized
to receive control (no treatment) or VX-970 administered
orally at 60 mg/kg once a day, four days a week, until
study endpoint (60 days). Animals were observed daily
and tumor volume and animal weight were measured
twice a week using a digital caliper and scale. Tumor
dimensions were converted to volume using the formula:
TV (mm3)=width2 (mm) × length (mm) × 0.52. Percent
tumor growth inhibition values were calculated and
reported for treatment group versus control using initial
and final tumor measurements.
Analysis of ATR expression in PDX tumor tissues
Proteins from frozen ACC PDX tumors were isolated
with the TissueLyzer II (QIAGEN, 85300) using 1.5 mm
beads. 120 μl RIPA buffer (50mM Tris-HCl pH 7.6,
150mM NaCl, 1% v/v NP-40, 0.5% w/v sodium deox-
ycholate, 0.1% w/v SDS) plus protease (Roche,
4693159001), and phosphatase (Sigma, P5726) inhibitors
were added to tumor samples, which were lysed at 30 Hz
for 40 s. The homogenized tissues were centrifuged at
12,000 × g for 5 min at 4 °C and the protein extracts were
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stored at −80 °C in Laemmli buffer to a final concentra-
tion of 1X. For Western Blot analysis, 20 μg of proteins
were loaded in 8% acrylamide gels, separated by electro-
phoresis and transferred onto nitrocellulose membranes
for 2 h at 4 °C. The membranes were blocked with 5%
milk in TBS containing 0.1% Tween-20 (TBS-T) and
incubated overnight at 4 °C with primary antibodies
against total ATR (Cell Signaling, 2790) or phospho-ATR
(Thr1989) (GeneTex, 128145) diluted 1:1000 in 5% BSA
in TBS-T. After washing three times for 5 min with TBS-
T, the membranes were incubated with an anti-rabbit
IgG-HRP antibody (Santa Cruz, sc-2313) diluted 1:10,000
in 5% BSA in TBS-T for 1 h at RT. Quantification of the
Western blots was carried out using ImageJ software.
RNA-sequencing (RNA-seq)
Ten ACC PDX tumors and six normal human salivary
gland tissues were collected in RNAlater (ThermoFisher)
and processed using TruSeq Stranded mRNA Library Kit
(Illumina). RNA extracted from these samples was
sequenced on an Illumina NovaSeq 6000 at a depth of
50M reads. Gene expression levels were determined from
RNA-seq after trimming reads for Illumina adapters with
Trimmomatic 0.36, aligning reads to the hg19 genome
with TopHat 2.1.1, and assigning reads to exons from the
TxDb.Hsapiens.UCSC.hg19.knownGene R package with
R 3.5.1. Differential gene expression between tumor and
normal salivary gland samples was calculated with
DESeq2 v1.20.0.
Global gene expression analysis
Biotin allonamide triphosphate-labeled cRNA from
transduced MCF10A cells was synthesized from total RNA
and hybridized to Human Gene 1.0 ST gene chips (Affy-
metrix, Santa Clara, CA) as recommended by the manu-
facturer. Probe summarization and quantile normalization
were carried out by Robust multiarray analysis (RMA)
using the Expression Console Software v1.1.2 (Affymetrix).
The microarray data are available from the Gene Expres-
sion Omnibus (GEO) database (Accession No.
GSE136095). Expression of ATR in cultured MYB-NFIB
positive ACC cells treated for 48 h with MYB siRNAs and
from serum-starved ACC cells treated for 24 h with IGF1R
inhibitors (linsitinib or BMS-754807) and insulin (5 μg/ml)
was analyzed from previously published microarray data
Accession No. GSE7609416. Co-expression of MYB and
ATR in acute myeloid leukemia (AML), adult T-cell acute
lymphoblastic leukemia (T-ALL), and colon carcinomas
and adenomas was analyzed with the publicly available R2
Genomics Platform (http://r2.amc.nl).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections from
tumors of the ACC PDX-model ACCX20M1 were
deparaffinized, and antigen epitopes were retrieved with
EnVision FLEX Target Retrieval Solution pH 9 (Agilent).
Slides were rinsed and endogenous peroxidase activity
was blocked with the EnVision Flex Mini Kit (Agilent).
Slides were incubated overnight at 4 °C with antibodies to
ATR (GTX128146) or p-ATR (S428, Abcam). Bound
antibodies were detected with HRP-conjugated secondary
antibodies and visualized with the EnVision FLEX DAB+
Chromogen substrate. Control sections were treated
identically but without primary antibodies. Stained sec-
tions were photographed with an Olympus BX45 micro-
scope (Tokyo, Japan) equipped with a Nikon Digital Sight
DS-U2 camera (Tokyo, Japan) and visualized with the
NIS-Elements F 2.30 software.
Statistical analysis
One-way ANOVA or independent samples t-tests were
used to estimate significant differences between groups
with post hoc F tests to confirm the assumption of equal
variance. All statistical tests were two-sided. A P value of
<0.05 was considered statistically significant. Non-linear
regression of dose-response experiments was carried out
in Prism 7 (Graphpad Software). Microarray data was
analyzed for differentially expressed genes and gene
ontologies with Nexus Expression 3.0 (BioDiscovery)
using the Benjamini–Hochberg method and false dis-
covery rate-corrected Q values of <0.05. Gene Set
Enrichment Analysis (GSEA) and heatmap visualization
were done with GSEA v3.0 (Broad Institute). Statistically
significant overlap between gene sets was estimated with
Chi-square tests.
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